Wockhardt Ltd
Wockhardt Ltd Q3 FY22 Results & Presentation Highlights: Revenue, Margins & Order Book
Q3 FY22 investor presentation: what the company reported on revenue, margins and projects.
Based on Wockhardt Ltd's Q3 FY22 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Net Sales Revenues for 9M FY22: INR 2,575 Cr (Page 4) - Profit After Tax (9M FY22): INR 32 Cr (Page 4) - EBITDA (9M FY22): INR 331 Cr (Page 4) - Year-on-year growth mentioned as 24% (Page 4) - Net Debt-Equity Ratio improved to 0.34x (Page 5) - International business contributes >80% of revenue (Page 4) - No explicit quarterly revenue or volume figures are provided. EBITDA (9M FY22): INR 331 Cr, showing 24% year-on-year growth (Page 4) - Profit After Tax (PAT) (9M FY22): INR 32 Cr, improved from -138 Cr (FY20-21) and -296 Cr (FY19-20) (Page 4) - Operating margin is not explicitly stated in the presentation.
From Wockhardt Ltd's Q3 FY22 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Net Sales Revenues for 9M FY22: INR 2,575 Cr (Page 4)
- Profit After Tax (9M FY22): INR 32 Cr (Page 4)
- EBITDA (9M FY22): INR 331 Cr (Page 4)
- Year-on-year growth mentioned as 24% (Page 4)
- Net Debt-Equity Ratio improved to 0.34x (Page 5)
- International business contributes >80% of revenue (Page 4)
2 more points management made on revenue & sales performance
Profitability & Margins
See what Wockhardt Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The presentation does not explicitly mention specific capex amounts, capacity expansions, or new plant/projects with detailed financials or timelines.
- It highlights manufacturing capacity readiness for diabetes biosimilars (insulin & GLP-1 analogs) for US, Europe, and emerging markets.
- Mentions global CMO supply for COVID-19 vaccines, with existing India & UK sites providing flexibility and >100 million doses supplied.
- Wockhardt selected under Indian Government’s Production Linked Incentive (PLI) Scheme, indicating potential investment support but no specific capex details shared.
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Wockhardt Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
Wockhardt Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹965 Cr, net profit ₹164 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Wockhardt Ltd's management said in earlier quarters
Frequently Asked Questions
What were Wockhardt Ltd Q3 FY22 results?
Net Sales Revenues for 9M FY22: INR 2,575 Cr (Page 4) - Profit After Tax (9M FY22): INR 32 Cr (Page 4) - EBITDA (9M FY22): INR 331 Cr (Page 4) - Year-on-year growth mentioned as 24% (Page 4) - Net Debt-Equity Ratio improved to 0.34x (Page 5) - International business contributes >80% of revenue (Page 4) - No explicit quarterly revenue or volume figures are provided. EBITDA (9M FY22): INR 331 Cr, showing 24% year-on-year growth (Page 4) - Profit After Tax (PAT) (9M FY22): INR 32 Cr, improved from -138 Cr (FY20-21) and -296 Cr (FY19-20) (Page 4) - Operating margin is not explicitly stated in the presentation.
What is Wockhardt Ltd share price analysis?
Wockhardt Ltd currently shows a neutral. The stock trades at a P/E of 85.0 with a market cap of ₹33,897 Cr. Investors should review the full earnings analysis for detailed insights.
Is Wockhardt Ltd planning capital expenditure?
The presentation does not explicitly mention specific capex amounts, capacity expansions, or new plant/projects with detailed financials or timelines.
Keep Wockhardt Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.